In Brief: Boston Scientific's NIR ON Ranger
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's NIR ON Ranger: Premarket approval application for the company's NIR coronary stent mounted on an over-the-wire catheter is submitted to FDA. Data from the NIRVANA stent trial, which was conducted by Boston Scientific's Medinol division, were submitted in support of the PMA. Boston Scientific also completes enrollment for a separate patient registry related to a NIR ON Ranger rapid-exchange delivery system that the company claims does not infringe patents held by competitors Guidant and Pfizer's Schneider unit. Results of the registry will be submitted as a PMA supplement, the company says...
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.